Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etrumadenant + mFOLFOX
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
**Etrumadenant + mFOLFOX** is a combination investigational cancer therapy consisting of **etrumadenant** (a selective dual antagonist of adenosine A2A and A2B receptors) and **modified FOLFOX** (mFOLFOX), a standard chemotherapy regimen. - Etrumadenant is designed to release anti-tumor immunity suppressed by adenosine signaling in the tumor microenvironment. - mFOLFOX is a chemotherapy regimen comprising oxaliplatin (a platinum-based alkylating agent), leucovorin (folinic acid, a coenzyme that enhances 5-FU efficacy), and fluorouracil (5-FU, a pyrimidine antimetabolite that inhibits DNA synthesis). - The combination is primarily in clinical evaluation for solid tumors, including colorectal cancer. - Etrumadenant was developed by Arcus Biosciences. - mFOLFOX is a well-established chemo backbone for various gastrointestinal malignancies and other cancers[1][2][3][4][5][6].
- Other names
- etrumadenant + modified FOLFOXetrumadenant + mFOLFOX6etrumadenant plus mFOLFOX
02
Targets
ADORA2A (Adenosine A₂A Receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA2B (Adenosine A2B receptor)
Beyond the preview
Go deeper on etrumadenant + mFOLFOX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etrumadenant + mFOLFOX.